The use of Zostavax in Spain: the economic case for vaccination of individuals aged 50 years and older

The use of Zostavax in Spain: the economic case for vaccination of individuals aged 50 years and older

The use of Zostavax in Spain: the economic case for vaccination of individuals aged 50 years and older
Although the VICP was originally created by Congress to shield drug companies producing government licensed, recommended and mandated vaccines for children, today it is not children but adults injured by influenza vaccine who are receiving most of the compensation. Zostavax vaccine has recently become available to prevent HZ and PHN. Letters can be submitted by e-mail, letters{at}healthaffairs.org, or the Health Affairs website, http://www.healthaffairs.org. We are grateful to Mark Ard for the opportunity to clarify an issue in our article (Feb 2016). A live webcast of the presentation can be accessed by visiting the “Events and Presentations” tab of the investor relations section of the Genocea website at http://ir.genocea.com. There are diseases such as herpes, RSV, chlamydia, malaria – the list is long – without good prevention or treatments. Sensitivity analyses showed that the model was most sensitive to the HZ and PHN epidemiological data, the health state utilities values, and vaccine price used.

Under the 1986 law, the only adult vaccine injury claims that can be compensated by the VICP are for injuries caused by vaccines recommended by the CDC for “universal use” by children.5 Most, but not all, of the CDC recommended vaccines for adults are also recommended for children.6 The shingles (herpes zoster) vaccine and 23-valent pneumococcal vaccine (PNEUMOVAX 23) recommended for adults are not eligible for compensation under the VICP7 and federal health officials and the ACCV has wrestled in recent years with how to protect vaccine manufacturers and compensate adult vaccine injuries not covered by the VICP.

You may also like